» Authors » Eric Sparkes

Eric Sparkes

Explore the profile of Eric Sparkes including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 91
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Sparkes E, Markham J, Boyd R, Udoh M, Gordon R, Zaman H, et al.
RSC Med Chem . 2024 Jun; 15(6):2063-2079. PMID: 38911147
Synthetic cannabinoid receptor agonists (SCRAs) comprise the second largest class of new psychoactive substances (NPS), and typically α-amino acid moieties are incorporated as part of their design. Limited investigation has...
2.
Sparkes E, Maloney C, Markham J, Dane C, Boyd R, Gilchrist J, et al.
ACS Chem Neurosci . 2024 May; 15(11):2160-2181. PMID: 38766866
Synthetic cannabinoid receptor agonists (SCRAs) are a growing class of new psychoactive substances (NPS) commonly derived from an -alkylated indole, indazole, or 7-azaindole scaffold. Diversification of this core (at the...
3.
Sparkes E, Timmerman A, Markham J, Boyd R, Gordon R, Walker K, et al.
ACS Chem Neurosci . 2024 Apr; 15(9):1787-1812. PMID: 38597712
ADB-HEXINACA has been recently reported as a synthetic cannabinoid receptor agonist (SCRA), one of the largest classes of new psychoactive substances (NPSs). This compound marks the entry of the -hexyl...
4.
Ryalls B, Patel M, Sparkes E, Banister S, Finlay D, Glass M
Biochem Pharmacol . 2024 Feb; 222:116052. PMID: 38354957
The cannabinoid CB receptor (CB) is a G protein-coupled receptor (GPCR) with widespread expression in the central nervous system. This canonically G⍺-coupled receptor mediates the effects of Δ-tetrahydrocannabinol (THC) and...
5.
Webb H, Finlay D, Chen S, Vernall A, Sparkes E, Banister S, et al.
Forensic Toxicol . 2023 Jan; 41(1):114-125. PMID: 36652070
Purpose: AMB-FUBINACA is a synthetic cannabinoid receptor agonist (SCRA) which is primarily metabolised by hepatic enzymes producing AMB-FUBINACA carboxylic acid. The metabolising enzymes associated with this biotransformation remain unknown. This...
6.
Janssens L, Ametovski A, Sparkes E, Boyd R, Lai F, Maloney C, et al.
ACS Chem Neurosci . 2022 Dec; 14(1):35-52. PMID: 36530139
Over 200 synthetic cannabinoid receptor agonists (SCRAs) have been identified as new psychoactive substances. Effective monitoring and characterization of SCRAs are hindered by the rapid pace of structural evolution. Ahead...
7.
Sparkes E, Boyd R, Chen S, Markham J, Luo J, Foyzun T, et al.
Front Psychiatry . 2022 Oct; 13:1010501. PMID: 36245876
Synthetic cannabinoid receptor agonists (SCRAs) continue to make up a significant portion new psychoactive substances (NPS) detected and seized worldwide. Due to their often potent activation of central cannabinoid receptors...
8.
Markham J, Sparkes E, Boyd R, Chen S, Manning J, Finlay D, et al.
ACS Chem Neurosci . 2022 Apr; 13(8):1281-1295. PMID: 35404067
Synthetic cannabinoid receptor agonists (SCRAs) are a diverse class of new psychoactive substances (NPS). They commonly comprise -alkylated indole, indazole, or 7-azaindole scaffolds with amide-linked pendant amino acid groups. To...
9.
Sparkes E, Cairns E, Kevin R, Lai F, Grafinger K, Chen S, et al.
RSC Med Chem . 2022 Mar; 13(2):156-174. PMID: 35308023
Synthetic cannabinoid receptor agonists (SCRAs) remain one the most prevalent classes of new psychoactive substances (NPS) worldwide, and examples are generally poorly characterised at the time of first detection. We...
10.
Grafinger K, Vandeputte M, Cannaert A, Ametovski A, Sparkes E, Cairns E, et al.
Drug Test Anal . 2021 Apr; 13(7):1412-1429. PMID: 33908179
The present work is the last of a three-part study investigating a panel of 30 systematically designed synthetic cannabinoid receptor agonists (SCRAs) including features such as the 4-pentenyl tail and...